It’s always great to read about stem cell clinical trials that are looking encouraging. Stem cell clinical trials Proving a new therapy is safe and effective is so challenging. Remarkably, there are more than 9,300 stem cell clinical trials listed for a “stem cell” search on Clinicaltrials.gov. Of course, not all of these are actual […]
I’m fascinated by the idea of making food from cells grown in a lab and especially the newest idea of lab-grown chocolate. While lab-grown meat has gotten the most attention, (see my recent post on test-tube meat: Not Old MacDonald’s Farm: is the future lab-grown meat?) I’d say that the coolest application of making food from
Biotech California Cultured aims to sell lab-grown chocolate Read More »
Stem cell research relies on some unusual reagents at times including a cell culture product called Matrigel. One of the challenges with such reagents is that if they suddenly are back-ordered it could bring some research to a halt. Matrigel has been in short supply for the last year or so. These products also tend
What is Matrigel, why a shortage, & alternatives? Read More »
Happy New Year and get ready for another 364 more days of stem cell excitement and craziness in 2022. In the next day or two I’ll post my predictions for this new year. Recommended reads EO Wilson obit by Carl Zimmer in NYT. Who’s the next EO Wilson or someone like him with such big impact these
Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson Read More »
There are so many stem cell clinics out there that it can be hard to keep track of them and the news about them, but a big court victory against a Manhattan stem cell clinic by New York State Attorney General Letitia James is notable for several reasons. Injunction on Park Avenue Stem Cell clinic
New York wins $5.1 million in suit against Manhattan stem cell clinic Read More »
The stem cell field lost a great scientist and friend this week with the passing of Meri Firpo from metastatic breast cancer. I’m going to post a tribute to Meri from several of us sometime this coming week. I’m in a bit of a somber mood but still trying to write, read, and do all
Weekly stem cell reads: COVID, tail regeneration, aging Read More »
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »
One of my main research interests is in oncodevelopmental factors. These include factors that are important both for normal stem cell biology and development as well as driving cancer when misregulated. One example includes the MYC family of proto-oncogenes. When I was a postdoc I got especially interested in trying to understand the normal role
Weekly reads: oncodevelopmental factors, iPSC cancer vaccine, more Read More »
A new word has been added to the lexicon of human stem cell research – blastoids, aka “blastocyst-like structures.” Unlike the familiar three-layered embryo that emerges during the third week of prenatal development, the earlier blastocyst resembles a fluid-filled soccer ball, with a smear of cells on the interior face destined to develop into the
New lab-grown blastoids are strikingly similar to human embryos Read More »
Recently I was going through a list I’m updating of regenerative medicine biotech companies including Bluebird bio. Now just a few days later the world seems turned upside down for the firm and maybe to some degree for other companies doing related work. Bluebird bio blues: 2 trial participants get cancer News broke today that
Bluebird bio sickle cell gene therapy trial halted on cancer worry Read More »